SecBot SecBot
EFFECT ·Filed Sep 11, 2026

SPRO

Spero Therapeutics, Inc.
BEARISH
Impact 7/10
Horizonimmediate Processed2mo ago SEC9999999995-26-002937
IPO/offering going effective
Actionable Insight ▼ Bearish

The shelf effectiveness removes the final regulatory barrier for a massively dilutive ATM offering. Traders should expect near-term share issuance via Jefferies, likely at a discount to market, creating persistent downward pressure. Monitor daily volume and any 424B5 prospectus supplement filings for the first ATM takedown.

DirectionBearish
Confidencehigh
Horizonimmediate

SP001

◆ Mixed Named in this EFFECT
Impact
Phase
Phase 2-ready (Phase 1 completed in healthy volunteers and Sjögren's disease)
Time to market
5+ years (Phase 2 starting Q2 2027; IgG4-RD is an orphan indication but still requires Phase 2 and Phase 3)
Next catalyst
None dated

What to watchSP001 is a new pipeline asset for Spero, announced alongside a $105M non-dilutive royalty financing from Utebzi sales. Watch for the Phase 2 initiation in IgG4-RD (Q2 2027) as the next catalyst. The stock may re-rate on execution towards Phase 2 start, but the $1.1B milestone burden relative to Spero's ~$126M market cap is a significant overhang. Monitor Innovent's Phase 2 SjD data in China (early 2027) as a read-through for the mechanism.

How the stock moved after the report

BEARISH VIEWSTOCK ABOVE ENTRY AT T+20
Entry
$1.13
T+0 close · Sep 11, 2026 · via day close
Latest settled
+6.19%
T+20 · $1.20 · next T+60 in 20d
Vs SPY
+4.33%
α at T+20
Latest observation
−4.52%
T+45 · FF3 residual α
  1. T+0 · Sep 11 $1.13entry
  2. T+1 · 2mo ago +0.89%α +1.33% · $1.14
  3. T+5 · 2mo ago 0.00%α +0.34% · $1.13
  4. T+20 · 6w ago +6.19%α +4.33% · $1.20
  5. T+46 · todayOpen
  6. T+60 · in 20d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

The SEC declared effective Spero Therapeutics' S-3 shelf registration (File No. 333-298641) on September 10, 2026, enabling the company to sell up to $300M in securities, including an immediate $100M at-the-market (ATM) common stock offering via Jefferies. This follows a prior S-3 filing 14 days ago and comes at a $68M market cap for a clinical-stage biotech with no approved products, making the ATM size (1.4x market cap) massively dilutive. The effectiveness removes the final regulatory barrier for a dilutive capital raise to fund preclinical development of SP001, with no near-term revenue prospects.

Key Facts

  • S-3 shelf registration (File No. 333-298641) declared effective on September 10, 2026
  • Registration covers up to $300M in securities, including an immediate $100M ATM offering
  • ATM size ($100M) is approximately 1.4x the company's $68M market cap
  • Spero is a clinical-stage biotech with no approved products and no near-term revenue
  • Proceeds intended to fund development of SP001, a preclinical CD40L antibody licensed from Innovent
  • Prior S-3 filing was submitted 14 days ago on August 28, 2026

Financial Impact

Up to $300M in securities registered; $100M ATM offering represents ~147% dilution relative to current $68M market cap

dilutioncash

Risk Factors

  • Immediate dilution of up to 147% of current market cap from the $100M ATM offering
  • No approved products or near-term revenue to offset dilution
  • Preclinical pipeline (SP001) has high development risk and no near-term catalysts

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
0% bullish (6 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
EFFECT Filing (Primary)9999999995-26-002937
Document: 9999999995-26-002937-index.html9999999995-26-002937
Document: 9999999995-26-002937.txt9999999995-26-002937

Track record

17 reports on SPRO

Performance horizon

4 of 7 bullish or bearish reports moved the stock their way by T+5. Best: +14.59% at T+20 after the Mar 26, 2026 report. 5 of 7 went positive at some point.

Filters
  1. Nov 12, 20264d ago 8-K Neutral 4/10 Entry $0.9999 Now $0.9460 −5.39% settles Nov 20
  2. Nov 10, 20266d ago 3 Neutral 2/10 Entry $1.02 Now $0.9460 −7.25% settles Nov 18
  3. Nov 10, 20266d ago 8-K Neutral 2/10 Entry $1.02 Now $0.9460 −7.25% settles Nov 18
  4. Oct 27, 202620d ago 8-K Neutral 2/10 Entry $1.17 to $1.07 Now $0.9460 −19.15% ▼ −8.55% −7.83% vs SPY
  5. Sep 11, 20269w ago EFFECT Bearish 7/10 Viewing Entry $1.13 to $1.13 Now $0.9460 +16.28% · 0.00% −0.34% vs SPY
  6. Aug 28, 202611w ago 8-K Bearish 7/10 Entry $1.22 to $1.19 Now $0.9460 +22.46% ▲ +2.46% +2.32% vs SPY
  7. Aug 28, 202611w ago S-3 Bearish 7/10 Entry $1.22 to $1.19 Now $0.9460 +22.46% ▲ +2.46% +2.32% vs SPY
  8. Aug 12, 202613w ago Press Release Neutral 4/10 Entry $1.24 to $1.22 Now $0.9460 −23.71% ▼ −1.61% +0.35% vs SPY
  9. Jul 14, 202617w ago 8-K Bullish 8/10 Entry $1.70 to $1.44 Now $0.9460 −44.35% ▼ −15.29% −14.00% vs SPY
  10. Jul 14, 202617w ago Press Release Bullish 7/10 Entry $1.70 to $1.44 Now $0.9460 −44.35% ▼ −15.29% −14.00% vs SPY
Showing 10 of 17

US Market Status

Market Closed · Opens Wed (10h 26m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 11, 2026